SG Americas Securities LLC Sells 32,403 Shares of Elanco Animal Health Incorporated $ELAN

SG Americas Securities LLC trimmed its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 25.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 95,525 shares of the company’s stock after selling 32,403 shares during the period. SG Americas Securities LLC’s holdings in Elanco Animal Health were worth $2,162,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Elanco Animal Health by 71.1% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 27,857 shares of the company’s stock valued at $663,000 after purchasing an additional 11,580 shares during the last quarter. GAMMA Investing LLC increased its position in Elanco Animal Health by 34.1% during the fourth quarter. GAMMA Investing LLC now owns 11,691 shares of the company’s stock worth $265,000 after buying an additional 2,972 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Elanco Animal Health by 266.4% during the third quarter. JPMorgan Chase & Co. now owns 1,918,336 shares of the company’s stock valued at $38,635,000 after buying an additional 1,394,839 shares in the last quarter. New Mexico Educational Retirement Board bought a new position in Elanco Animal Health during the third quarter valued at about $1,998,000. Finally, CTC Alternative Strategies Ltd. acquired a new stake in shares of Elanco Animal Health in the third quarter worth about $220,000. Institutional investors own 97.48% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on ELAN shares. UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Friday, March 27th. Morgan Stanley upped their target price on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Piper Sandler upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price target for the company from $24.00 to $30.00 in a report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Elanco Animal Health from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.67.

Elanco Animal Health Price Performance

NYSE ELAN opened at $23.11 on Friday. The stock has a 50-day simple moving average of $24.56 and a 200 day simple moving average of $22.82. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $27.72. The stock has a market capitalization of $11.49 billion, a PE ratio of -48.14, a P/E/G ratio of 2.94 and a beta of 1.88. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The company’s revenue was up 12.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.14 EPS. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.